Genomics plc, an Oxford, UK-based data science company specializing in the use of human genetic information to improve drug development, closed a £25m Series B financing.
The round was led by Vertex Pharmaceuticals with participation from IP Group plc, Woodford Investment Management Ltd, Invesco Perpetual, Oxford Sciences Innovation (OSI), Lansdowne Partners and Tanarra.
The company intends to use the funds to enable further expansion, to continue to enhance its database and to pursue opportunities that emerge in this space.
Formed in 2014 by four scientists at the University of Oxford, including Professors Peter Donnelly (then Director of the Wellcome Centre for Human Genetics) and Gil McVean (Director of Oxford’s Big Data Institute), Genomics has developed an analysis engine which uses genetics to understand human biology and the likely efficacy and safety of potential novel medicines. The engine has over 100 billion data points and links human genetic variation at over 14 million positions in the human genome to changes in 7,000 molecular, cellular, and physiological measurements and disease outcomes.
The company uses proprietary machine learning and statistical algorithms to predict the impact of therapeutic interventions.
Genomics has also announced a collaboration with Vertex to further advance the latter’s efforts to develop transformative medicines for people with serious diseases.